LPA基因变异与冠心病风险的关联及对脂蛋白(a)降低治疗的启示:孟德尔随机化分析
结果显示遗传预测Lp(a)每降低10 mg/dL,冠心病风险降低5.8%(OR 0.942,95%CI 0.933-0.951),而LDL-C每降低10 mg/dL风险降低14.5%(OR 0.855,95%CI 0.818-0.893);Lp(a)需降低约101.5 mg/dL才与LDL-C降低38.67 mg/dL的关联程度相当。
要点
- 遗传预测Lp(a)与冠心病风险的关联呈线性,每降低10 mg/dL风险降低5.8%。
- Lp(a)降低约101.5 mg/dL才相当于LDL-C降低38.67 mg/dL的冠心病风险关联。
- Lp(a)与冠心病风险的关联独立于他汀、PCSK9抑制剂和依折麦布模拟的LDL-C变化。
核心结论
- 降低Lp(a)的临床获益可能与其绝对降低幅度成比例。
- 可能需要约100 mg/dL的大幅Lp(a)绝对降低才能产生与LDL-C降低38.67 mg/dL(1 mmol/L)相似幅度的临床意义冠心病风险降低。
研究设计与样本
- 孟德尔随机化分析,使用5项研究的个体参与者数据进行主分析,并利用48项研究的汇总数据进行外部验证。
主要发现
- 遗传预测Lp(a)浓度每降低10 mg/dL,冠心病风险降低5.8%(OR 0.942,95%CI 0.933-0.951,P=3×10^-37)。
- 遗传预测LDL-C每降低10 mg/dL,冠心病风险降低14.5%(OR 0.855,95%CI 0.818-0.893,P=2×10^-12)。
- Lp(a)浓度变化101.5 mg/dL(95%CI 71.0-137.0)与LDL-C变化38.67 mg/dL对冠心病风险的关联程度相同。
- 遗传预测Lp(a)与冠心病风险的关联似乎独立于模拟他汀、PCSK9抑制剂和依折麦布作用的遗传变异所导致的LDL-C变化。
关键数值与推荐
- 遗传预测Lp(a)每降低10 mg/dL与冠心病风险降低5.8%相关(OR 0.942,95%CI 0.933-0.951)。
- 遗传预测LDL-C每降低10 mg/dL与冠心病风险降低14.5%相关(OR 0.855,95%CI 0.818-0.893)。
- Lp(a)变化101.5 mg/dL(95%CI 71.0-137.0)与LDL-C变化38.67 mg/dL(1 mmol/L)的冠心病风险关联等效。
临床怎么用
- Lp(a)降低治疗的临床获益应依据Lp(a)绝对降低幅度评估,而非仅看相对百分比。
- 若目标为达到与LDL-C降低38.67 mg/dL相当的冠心病风险降低,Lp(a)可能需要降低约100 mg/dL。
局限性
- 参与者均为欧洲白人 ancestry,结果外推至其他种族人群需谨慎。
- 分析基于遗传预测的Lp(a)和LDL-C水平,而非直接药物干预试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Human genetic studies have indicated that plasma lipoprotein(a) (Lp[a]) is causally associated with the risk of coronary heart disease (CHD), but randomized trials of several therapies that reduce Lp(a) levels by 25% to 35% have not provided any evidence that lowering Lp(a) level reduces CHD risk. OBJECTIVE: To estimate the magnitude of the change in plasma Lp(a) levels needed to have the same evidence of an association with CHD risk as a 38.67-mg/dL (ie, 1-mmol/L) change in low-density lipoprotein cholesterol (LDL-C) level, a change that has been shown to produce a clinically meaningful reduction in the risk of CHD. DESIGN, SETTING, AND PARTICIPANTS: A mendelian randomization analysis was conducted using individual participant data from 5 studies and with external validation using summarized data from 48 studies. Population-based prospective cohort and case-control studies featured 20 793 individuals with CHD and 27 540 controls with individual participant data, whereas summarized data included 62 240 patients with CHD and 127 299 controls. Data were analyzed from November 2016 to March 2018. EXPOSURES: Genetic LPA score and plasma Lp(a) mass concentration. MAIN OUTCOMES AND MEASURES: Coronary heart disease. RESULTS: Of the included study participants, 53% were men, all were of white European ancestry, and the mean age was 57.5 years. The association of genetically predicted Lp(a) with CHD risk was linearly proportional to the absolute change in Lp(a) concentration. A 10-mg/dL lower genetically predicted Lp(a) concentration was associated with a 5.8% lower CHD risk (odds ratio [OR], 0.942; 95% CI, 0.933-0.951; P = 3 × 10-37), whereas a 10-mg/dL lower genetically predicted LDL-C level estimated using an LDL-C genetic score was associated with a 14.5% lower CHD risk (OR, 0.855; 95% CI, 0.818-0.893; P = 2 × 10-12). Thus, a 101.5-mg/dL change (95% CI, 71.0-137.0) in Lp(a) concentration had the same association with CHD risk as a 38.67-mg/dL change in LDL-C level. The association of genetically predicted Lp(a) concentration with CHD risk appeared to be independent of changes in LDL-C level owing to genetic variants that mimic the relationship of statins, PCSK9 inhibitors, and ezetimibe with CHD risk. CONCLUSIONS AND RELEVANCE: The clinical benefit of lowering Lp(a) is likely to be proportional to the absolute reduction in Lp(a) concentration. Large absolute reductions in Lp(a) of approximately 100 mg/dL may be required to produce a clinically meaningful reduction in the risk of CHD similar in magnitude to what can be achieved by lowering LDL-C level by 38.67 mg/dL (ie, 1 mmol/L).
引用
- Burgess S, Ference BA, Staley JR, et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol. 2018. PMID: 29926099. doi:10.1001/jamacardio.2018.1470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。